Summer Sale

50% off Premium Yearly

00days
00hrs
00mins
00secs
SII.TO 3.78IPCO.TO 0.08DC.A.TO 0.1NESN-SIX 0MCK 9.94GOOG -1.89XLV -0.22TEVA 0.83
Pfizer Inc (PFE)

NYSE:PFE

Pfizer Inc (PFE)

27.95
-0.02 (0.07%)
as of Aug 25, 2026, 1:34:22 pm Market Open.
582 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
Investor Insights
star iconAug 24, 2026, 12:00 am

This summary was created by AI, based on 24 opinions in the last 12 months.

Pfizer Inc. (PFE) is facing significant challenges as its revenue streams have been impacted by the end of the COVID vaccine boom and a looming patent cliff. Many experts express concerns over the company's limited pipeline for new blockbuster drugs, especially as previous successful drugs have come off patent. Despite these challenges, Pfizer offers an attractive dividend yield which has been highlighted across many reviews, providing a tempting incentive for investors. Some experts suggest it might be a good long-term hold due to potential growth in areas like oncology and obesity, although the company's future growth prospects remain uncertain. The general sentiment suggests that while some see PFE as a value play, caution is advised given the current dynamics of its business model.

consensus icon
Consensus
Neutral
valuation icon
Valuation
Undervalued
review icon
Similar
NVO
DON'T BUY

Pfizer Inc(PFE)

Dec 28, 2001
Very expensive. US drug companies are having problems.
Photo of Brian Acker, CABrian Acker, CAUnlock Rating
$40.40

Stock price when the opinion was issued

$28.41

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Dec 19, 2001
Good cash flow. Will grow 20% + 2002/03 and 15% 2004. A good price.
Photo of Michelle CalpinMichelle CalpinUnlock Rating
$41.10

Stock price when the opinion was issued

$28.41

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Dec 17, 2001
Excellent company. Good dividends.
Photo of Bob StodgellBob StodgellUnlock Rating
$40.33

Stock price when the opinion was issued

$28.41

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Dec 12, 2001
Great company, but economy is hitting all drug companies. Too high now.
Photo of Paul O'NeilPaul O'NeilUnlock Rating
$40.24

Stock price when the opinion was issued

$28.41

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

Nov 28, 2001
(Was a top pick on Sept 26 up 16%) Still likes. A lot more upside yet.
Photo of Joe ConnollyJoe ConnollyUnlock Rating
$43.17

Stock price when the opinion was issued

$28.41

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Nov 28, 2001
Has a good pipeline for new drugs.
Photo of Mark Jackson, CFAMark Jackson, CFAUnlock Rating
$43.17

Stock price when the opinion was issued

$28.41

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
BUY ON WEAKNESS

Pfizer Inc(PFE)

Nov 08, 2001
Good products. Buy on weakness.
Photo of Brendan CaldwellBrendan CaldwellUnlock Rating
$42.30

Stock price when the opinion was issued

$28.41

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Oct 30, 2001
One of the best drug companies.
Photo of Neil MurdockNeil MurdockUnlock Rating
$42.45

Stock price when the opinion was issued

$28.41

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
Track your Stocks in your Watch List
PAST TOP PICK

Pfizer Inc(PFE)

Oct 30, 2001
(Was a top pick on April 12 up 4.6%) Good sector.
Photo of Neil MurdockNeil MurdockUnlock Rating
$42.45

Stock price when the opinion was issued

$28.41

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Oct 25, 2001
Trades in a range. Good company.
Photo of Brendan CaldwellBrendan CaldwellUnlock Rating
$43.01

Stock price when the opinion was issued

$28.41

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Sep 27, 2001
Stable. Trading in the mid $20's is an earning multiple based on the 15% growth expected. Has competition.
Photo of Gordon Higgins, CA, MBAGordon Higgins, CA, MBAUnlock Rating
$39.75

Stock price when the opinion was issued

$28.41

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Sep 26, 2001
A defense stock. Ability to produce new drugs. Great patent protection. Great product line.
Photo of Joe ConnollyJoe ConnollyUnlock Rating
$38.55

Stock price when the opinion was issued

$28.41

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Sep 24, 2001
Likes. Best product line and a good pipeline. AT a good price.
Photo of Brendan CaldwellBrendan CaldwellUnlock Rating
$36.03

Stock price when the opinion was issued

$28.41

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Sep 24, 2001
Cheap. Great pipeline. Low risk.
Photo of Glenn Paradis, BA, CFAGlenn Paradis, BA, CFAUnlock Rating
$36.03

Stock price when the opinion was issued

$28.41

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Sep 21, 2001
Should do well even in a recession. Good price.
Photo of Steven WipperstegSteven WipperstegUnlock Rating
$35.80

Stock price when the opinion was issued

$28.41

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
Showing 841 to 855 of 887 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

NTR.TO -2.98$99.89
TFPM 0$
OGC.TO -0.83$42.39
SLB 0.045$54.045
ARG.TO 0.33$8.55

Today's Top Picks

SII.TO 3.78$190.97
IPCO.TO 0.08$35.3
DC.A.TO 0.1$5.25
NESN-SIX 0$
MCK 9.94$883.73

Popular Articles

Latest Sell Signals

RKLB -1.05$67.23
INTC 1.21$88.47
MSFT 1.63$488.94
WSP.TO -0.96$191.32
CLS.TO 10.72$418.08

Most Recent Experts

Rick Rule

Rick Rule

Rule Investment Media

Jim Cramer - Mad Money

Jim Cramer - Mad Money

CNBC

Larry Berman CFA, CMT, CTA

Larry Berman CFA, CMT, CTA

ETF Capital Management Inc.

Rob Sechan, Managing Partner, New Edge Capital

Rob Sechan, Managing Partner, New Edge Capital

New Edge Capital

Jenny Harrington, CEO, Gilman Hill Asset Management

Jenny Harrington, CEO, Gilman Hill Asset Management

Gilman Hill Asset Management

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica

You may also like